TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial

What's the purpose of the trial?

This research study is assessing the efficacy of MBG-453, a humanized monoclonal antibody, in treating myelodysplastic syndromes (MDS). The name of the study drug involved in this study is MBG453.
Trial status

Accepting patients

Phase 2
Last Updated
2 months ago
Am I Eligible

Participating Centers

There are 3 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Sabatolimab is a kind of drug called a TIM-3 monoclonal antibody that targets the TIM-3 protein found on the surface of several different types of cells in the immune system.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients


Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.